GlassScriptPhysician profile
Anthony H Weiss
NPI 1962430488
$24,033.19
in general payments reported to CMS, 2019-2025
38 companies · $4,995 in 2025
The $4,995 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,758 · 2020: $1,278 · 2021: $3,209 · 2022: $4,142 · 2023: $3,680 · 2024: $3,972 · 2025: $4,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,624.26 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,682.47 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $3,553.78 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,771.94 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $2,141.48 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $2,007.76 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $1,500.94 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $1,223.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $751.18 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $551.85 | 2019-2023 | Clenpiq |
| Aimmune Therapeutics, INC. | $433.74 | 2024-2025 | Vowst, Zenpep |
| Ucb, INC. | $391.15 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $385.35 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $383.84 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $373.30 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $367.77 | 2024-2025 | Ibsrela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.